2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3694 Glofitamab and polatuzumab vedotin with dose adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Glo-PERCH) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas

Ryan C Lynch, MD, Paul S Martin, MD2, Mengyang Di, MD, PhD3, Jennifer J. Huang, MD, PhD4, Vikram Raghunathan, MD5, Mazyar Shadman, MD, MPH6, Stephen Douglas Smith, MD7, Chaitra Ujjani, MD8, Brian G Till, MD9, Heather Rasmussen10, Ted Gooley, PhD11, Jenna Voutsinas, MPH12, Ajay Gopal, MD13
1 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States

Introduction

We previously published and presented results of a phase 1 study with dose expansion examining the safety and efficacy of substituting polatuzumab vedotin for vincristine as part of the dose-adjusted EPOCH-R regimen (PERCH) (Lynch RC et al. Blood Advances 2023; Lynch RC et al. ICML 2025, NCT04231877). Since the conception of that study, CD3×CD20 bispecific antibodies have been approved for relapsed large B-cell lymphoma and are increasingly being investigated in earlier lines of therapy, with promising early results. Therefore, we designed a new regimen integrating glofitamab with PERCH.

Methods

This was a single-center, open-label, investigator-initiated clinical trial of 6 cycles of glofitamab plus PERCH (Glo-PERCH). Eligible patients must have been destined to receive DA-EPOCH-R as the standard of care regimen if treated outside of a trial. We utilized the original PERCH regimen, as previously published, and added glofitamab beginning on cycle 2, day 1, using the standard step-up dose of 2.5 mg intravenously. The second step-up dose (10 mg IV) was administered on cycle 2, day 8, and the target dose (30 mg IV) was administered on cycle 3, day 1. Polatuzumab vedotin was administered at 1.8 mg/kg on day 1 of each cycle, as previously published. All other components of the regimen, including escalation of chemotherapy dosing based on neutrophil and platelet nadirs from the preceding cycle, were administered according to the previously published dose-adjusted EPOCH-R regimen (Dunleavy et al. N Engl J Med 2013).

The primary objective was to estimate the safety of Glo-PERCH, as measured by the rate of dose-limiting toxicities between cycle 2, day 1, and cycle 4, day 1, reflecting the period during which glofitamab was introduced into the original regimen. Prespecified suspension rules were designed to be triggered if the lower limit of an 80% confidence interval could not exclude a DLT rate greater than 20%. Secondary and exploratory objectives included analyses of efficacy, survival, and MRD using PhasED-Seq.

Results

Eighteen patients enrolled between October 10, 2024, and May 6, 2026. All patients received at least one dose of study treatment and were evaluable for safety, and all had undergone at least one response assessment. The median age was 54 years (range, 19–74). Eight serious adverse events occurred in 6 patients (33%), including 7 episodes of grade 3 or higher febrile neutropenia and 1 episode of grade 3 hyperglycemia. Other grade 3 or higher nonhematologic adverse events included ALT elevation (2, 11%), syncope (2, 11%), alkaline phosphatase elevation (1, 6%), AST elevation (1, 6%), diarrhea (1, 6%), oral mucositis (1, 6%), pain (1, 6%), and venous thromboembolism (1, 6%). Peripheral sensory neuropathy occurred in 9 patients (50%), with all events grade 1. One patient (6%) experienced grade 2 peripheral motor neuropathy. Four episodes (22%) of cytokine release syndrome were observed, all grade 1, and no doses of tocilizumab were administered. Two patients (11%) experienced dose reduction or discontinuation of polatuzumab vedotin due to toxicities occurring during cycle 1, before the first dose of glofitamab, and were therefore not evaluable for DLT. Among the 16 DLT-evaluable patients, 1 DLT was observed, consisting of a delay in glofitamab administration due to grade 3 hyperglycemia and therefore the study’s primary endpoint was met.

Sixteen patients completed all study therapy and underwent an end-of-treatment response assessment. The end-of-treatment ORR was 87%, including a CR rate of 56%. At a median follow-up of 12.9 months, the estimated 1-year progression-free survival was 88%, and the estimated 1-year overall survival was 100%. Two patients (13%) had PD by end-of-treatment imaging. One had biopsy-confirmed progression immediately following therapy and has since succumbed to their disease. The other underwent biopsy demonstrating ghost cells without evidence of viable malignancy and remains on surveillance without subsequent progression. MRD analyses will be performed and presented at a future date.

Conclusion

Integrating glofitamab into the PERCH regimen was safe and feasible. Cytokine release syndrome was uncommon, low grade, and manageable. Early efficacy results are promising in this high-risk population, although residual FDG uptake on end-of-treatment PET scans was relatively frequent despite the absence of biopsy-confirmed active lymphoma or disease progression in most cases.

Ryan C Lynch, MD: Merck - Honoraria; Janssen - Research Funding; Genentech - Research Funding; Cyteir - Research Funding; Rapt Therapeutics - Research Funding; Allogene - Research Funding; Incyte - Research Funding; Pfizer - Research Funding; Merck - Research Funding; Natera - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Foresight Diagnostics - Consultancy (Includes expert testimony)